Privium Fund Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Privium Fund Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Sell	90,110 -80,146	-47%	-$781K	0.22%	43
2026 Q1	$1.59M	Sell	170,256 -39,744	-19%	-$346K	0.33%	37
2025 Q4	$1.57M	Buy	210,000 +12,542	+6%	+$127K	0.29%	36
2025 Q3	$1.72M	Hold	197,458	–	–	0.31%	33
2025 Q2	$819K	Buy	197,458 +66,458	+51%	+$234K	0.18%	37
2025 Q1	$423K	Buy	131,000 +10,000	+8%	+$47.1K	0.11%	45
2024 Q4	$674K	Buy	121,000 +22,500	+23%	+$177K	0.15%	39
2024 Q3	$1.06M	Buy	98,500 +58,500	+146%	+$971K	0.26%	34
2024 Q2	$823K	Buy	40,000 +9,000	+29%	+$226K	0.21%	48
2024 Q1	$988K	Sell	31,000 -2,680	-8%	-$68.4K	0.26%	43
2023 Q4	$716K	Hold	33,680	–	–	0.2%	51
2023 Q3	$429K	Buy	+33,680	New	+$563K	0.13%	61

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Privium Fund Management's FDMT Position: Q2 2026 in Review

Privium Fund Management reduced its 4D Molecular Therapeutics (FDMT) stake by 47% in Q2 2026, selling an estimated $781K and leaving 90,110 shares worth $1.2M. The position accounts for 0.22% of the portfolio, ranked #43.

Privium Fund Management first reported a position in FDMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.72M in Q3 2025. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Privium Fund Management held 90,110 shares of 4D Molecular Therapeutics worth $1.2M as of Q2 2026.
Privium Fund Management sold 80,146 4D Molecular Therapeutics shares in Q2 2026, an estimated $781K.
4D Molecular Therapeutics made up 0.22% of Privium Fund Management's portfolio in Q2 2026, its #43 holding.
Privium Fund Management first reported a position in 4D Molecular Therapeutics in Q3 2023 and has held it in 12 quarters since.
Privium Fund Management's 4D Molecular Therapeutics position peaked at $1.72M in Q3 2025.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.